AR095721A1 - Derivados de piridina - Google Patents

Derivados de piridina

Info

Publication number
AR095721A1
AR095721A1 ARP140101336A ARP140101336A AR095721A1 AR 095721 A1 AR095721 A1 AR 095721A1 AR P140101336 A ARP140101336 A AR P140101336A AR P140101336 A ARP140101336 A AR P140101336A AR 095721 A1 AR095721 A1 AR 095721A1
Authority
AR
Argentina
Prior art keywords
alkyl
pyrrolidinyl
cycloalkyl
azetidinyl
aza
Prior art date
Application number
ARP140101336A
Other languages
English (en)
Inventor
Gavelle Olivier
Grether Uwe
Kimbara Atsushi
Nettekoven Matthias
Rogers-Evans Mark
Rombach Didier
Schulz-Gasch Tanja
Roever Stephan
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR095721A1 publication Critical patent/AR095721A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

Reivindicación 1: Un compuesto de la fórmula (1), en la que A es un compuesto seleccionado del grupo de fórmulas (2); R¹ es hidrógeno o halógeno; R² es halógeno, cicloalquilo, haloazetidinilo, 6-oxa-1-aza-espiro[3.3]heptilo o alquilsulfonilo; R³ es -OR⁸, pirrolidinilo, halopirrolidinilo, hidroxi-pirrolidinilo, morfolinilo, cicloalquilsulfonilo, alcoxi-azetidinilo, 2-oxa-6-aza-espiro[3.3]heptilo o 2-oxa-7-aza-espiro[3.4]heptilo; R⁴ es hidrógeno, alquilo, hidroxialquilo, alcoxialquilo, haloalquilo, cicloalquilo, hidroxicicloalquilo, alquil-cicloalquilo, aminocarbonilcicloalquilo, fenilo, fenil-alquilo, alquiloxetanilo, azetidinilo o aminooxetanilo; R⁵ es hidrógeno, alquilo o alquiloxadiazolilo; o R⁴ y R⁵, junto con el átomo de carbono, al que están unidos, forman un cicloalquilo; R⁶ es alquilo; R⁷ es alquilo; y R⁸ es haloalquilo, alcoxialquilo, cicloalquilalquilo, haloalquilo, halofenilo, oxetanilo, oxetanilalquilo, alquil-oxetanilalquilo, tetrahidrofuranilo, tetrahidrofuranilalquilo, alquilsulfonilfenilo, alquilpirrolidinilo, alquil-pirrolidinilalquilo, azetidinilo, morfolinilalquilo, tetra-hidropiranilo, pirrolidinilalquilo, piperidinilo, piperidinilalquilo, alquilpiperidinilalquilo, alquil-piperidinilo, dialquilaminoalquilo, piridinilalquilo, halo-oxetanilalquilo, dialquiloxazolilalquilo, alquiloxazolil-alquilo, halopiridinilalquilo o morfolinilo; o una sal o éster farmacéuticamente aceptable del mismo.
ARP140101336A 2013-03-26 2014-03-25 Derivados de piridina AR095721A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13161176 2013-03-26

Publications (1)

Publication Number Publication Date
AR095721A1 true AR095721A1 (es) 2015-11-04

Family

ID=47913322

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140101336A AR095721A1 (es) 2013-03-26 2014-03-25 Derivados de piridina

Country Status (34)

Country Link
US (2) US10308659B2 (es)
EP (1) EP2978755B1 (es)
JP (1) JP6500010B2 (es)
KR (1) KR20150135458A (es)
CN (1) CN105121436B (es)
AR (1) AR095721A1 (es)
AU (1) AU2014243190B2 (es)
BR (1) BR112015024272A2 (es)
CA (1) CA2899168A1 (es)
CL (1) CL2015002835A1 (es)
CR (1) CR20150440A (es)
DK (1) DK2978755T3 (es)
EA (1) EA027569B1 (es)
ES (1) ES2661737T3 (es)
HK (1) HK1211938A1 (es)
HR (1) HRP20180371T1 (es)
HU (1) HUE036934T2 (es)
IL (1) IL240496B (es)
LT (1) LT2978755T (es)
MA (1) MA38404B1 (es)
MX (1) MX365921B (es)
MY (1) MY174000A (es)
NO (1) NO2978755T3 (es)
PE (1) PE20151559A1 (es)
PH (1) PH12015501933A1 (es)
PL (1) PL2978755T3 (es)
PT (1) PT2978755T (es)
RS (1) RS56927B1 (es)
SG (1) SG11201507994QA (es)
SI (1) SI2978755T1 (es)
TW (1) TWI628174B (es)
UA (1) UA116239C2 (es)
WO (1) WO2014154612A1 (es)
ZA (1) ZA201505251B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9708341B2 (en) * 2014-06-09 2017-07-18 Sumitomo Chemical Company, Limited Method for producing pyridine compound
CR20180298A (es) * 2015-12-09 2018-07-18 Hoffmann La Roche Nuevos derivados de fenilo
PL3481201T3 (pl) * 2016-07-07 2021-03-22 Corteva Agriscience Llc Sposoby wytwarzania 4-alkoksy-3-(acylo lub alkilo)oksypikolinamidów
TW202334101A (zh) * 2017-04-06 2023-09-01 美商富曼西公司 殺真菌之噁二唑
EP3642200B1 (en) 2017-06-20 2023-05-03 F. Hoffmann-La Roche AG Pyridine derivatives
WO2019003956A1 (ja) * 2017-06-27 2019-01-03 住友化学株式会社 オキサジアゾール化合物及びその用途
CN108774220B (zh) * 2018-05-27 2019-04-23 西安培华学院 用于治疗心肌缺血的化合物及其应用
CN112638430B (zh) 2018-06-27 2023-05-16 豪夫迈·罗氏有限公司 放射性标记的大麻素受体2配体
WO2020002270A1 (en) 2018-06-27 2020-01-02 F. Hoffmann-La Roche Ag Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists
PE20210368A1 (es) 2018-06-27 2021-02-26 Eth Zuerich Nuevos compuestos de piridina y pirazina como inhibidores del receptor cannabinoide 2
CN114195759B (zh) * 2021-08-26 2023-10-20 上海零诺生物科技有限公司 一种2-甲基-5-（1-甲基吡咯烷-2-基）吡啶制备方法
EP4419508A2 (en) * 2021-10-22 2024-08-28 Carmot Therapeutics, Inc. Oxazole, oxadiazole, and indole derivatives for the inhibition of usp28
CN115073366B (zh) * 2022-06-08 2024-08-09 都创(重庆)医药科技有限公司 一种基于微通道技术快速制备3-氯吡啶-2-甲酸的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2479744A1 (en) * 2002-03-28 2003-10-09 Paul E. Finke Substituted 2,3-diphenyl pyridines
JP5406716B2 (ja) * 2006-08-07 2014-02-05 アイアンウッド ファーマシューティカルズ インコーポレイテッド インドール化合物
US20100227845A1 (en) * 2007-10-18 2010-09-09 Zhicai Wu Substituted 1,2,4-oxadiazoles and analogs thereof as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
US9321727B2 (en) 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
UA111640C2 (uk) 2011-11-08 2016-05-25 Ф. Хоффманн-Ля Рош Аг ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2
EP2870139B1 (en) 2012-07-04 2016-06-15 F.Hoffmann-La Roche Ag Novel adamantyl derivatives as cannabinoid receptor 2 agonists
MX2015007155A (es) 2012-12-07 2015-10-14 Hoffmann La Roche Nuevos derivados de piridina.
PE20151089A1 (es) 2012-12-07 2015-08-06 Hoffmann La Roche Piridin-2-amidas utiles como agonistas de cb2
MX2015007156A (es) 2012-12-07 2015-10-14 Hoffmann La Roche Piridina-2-amidas utiles como agonistas receptores de canabinoides 2 (cb2).
IN2015DN03145A (es) 2012-12-07 2015-10-02 Hoffmann La Roche
PL2964646T3 (pl) 2013-03-07 2017-09-29 F.Hoffmann-La Roche Ag Nowe pochodne pirazolu
PE20161370A1 (es) 2014-04-04 2016-12-17 Hoffmann La Roche Nuevos derivados de piridina utiles como antagonistas de cb2
AR099932A1 (es) 2014-04-04 2016-08-31 Hoffmann La Roche Derivados de piridina

Also Published As

Publication number Publication date
HRP20180371T1 (hr) 2018-04-06
TW201518287A (zh) 2015-05-16
AU2014243190A1 (en) 2015-07-30
IL240496A0 (en) 2015-09-24
MA38404A1 (fr) 2017-01-31
ZA201505251B (en) 2016-07-27
MA38404B1 (fr) 2017-09-29
DK2978755T3 (en) 2018-03-05
PH12015501933B1 (en) 2016-01-11
UA116239C2 (uk) 2018-02-26
US20190248803A1 (en) 2019-08-15
US10308659B2 (en) 2019-06-04
CA2899168A1 (en) 2014-10-02
ES2661737T3 (es) 2018-04-03
US20160016968A1 (en) 2016-01-21
BR112015024272A2 (pt) 2017-07-18
JP6500010B2 (ja) 2019-04-10
CN105121436A (zh) 2015-12-02
MY174000A (en) 2020-03-03
PH12015501933A1 (en) 2016-01-11
HK1211938A1 (en) 2016-06-03
PE20151559A1 (es) 2015-11-05
EA027569B1 (ru) 2017-08-31
IL240496B (en) 2019-03-31
EP2978755A1 (en) 2016-02-03
JP2016516737A (ja) 2016-06-09
PT2978755T (pt) 2018-02-26
WO2014154612A1 (en) 2014-10-02
EP2978755B1 (en) 2018-01-03
PL2978755T3 (pl) 2018-05-30
SG11201507994QA (en) 2015-10-29
HUE036934T2 (hu) 2018-08-28
SI2978755T1 (en) 2018-03-30
MX2015013629A (es) 2016-02-18
KR20150135458A (ko) 2015-12-02
MX365921B (es) 2019-06-20
CN105121436B (zh) 2018-07-27
NO2978755T3 (es) 2018-06-02
RS56927B1 (sr) 2018-05-31
EA201591567A1 (ru) 2016-01-29
CL2015002835A1 (es) 2016-05-20
TWI628174B (zh) 2018-07-01
AU2014243190B2 (en) 2018-07-19
LT2978755T (lt) 2018-03-12
CR20150440A (es) 2015-10-08

Similar Documents

Publication Publication Date Title
AR095721A1 (es) Derivados de piridina
AR102539A1 (es) Triazolo[4,5-d]pirimidinas
AR093843A1 (es) Derivados de piridina agonistas de receptores cb2
AR101189A1 (es) Heterociclos nitrogenados antiproliferativos y sus métodos de uso
AR096152A1 (es) Derivados de purina
AR093806A1 (es) Derivados de piridina agonistas de receptores cb2
AR099177A1 (es) Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
AR092973A1 (es) Benzamidas
AR094978A1 (es) Derivados de pirazol agonistas de receptores canabinoides
AR090220A1 (es) Inhibidores de serina/treonina cinasa
AR095198A1 (es) Derivados de triazolona de piridinilo y piridinilo fusionado
AR093805A1 (es) Derivados de piridina agonistas del receptor 2 de cannabinoides
AR090967A1 (es) Picolinamidas macrociclicas como fungicidas
AR090587A1 (es) Compuestos triciclicos sustituidos con actividad hacia los receptores ep1
AR103742A1 (es) Derivados de trifluorometilpropanamida
AR093804A1 (es) Derivados de pirazina agonistas de receptores cb2
AR105653A1 (es) Derivados del ácido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del virus de la inmunodeficiencia humana
AR105991A1 (es) Heteroarilos sustituidos con pirazolilo y su uso como medicamentos
AR099932A1 (es) Derivados de piridina
AR107321A1 (es) Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos
AR096153A1 (es) Derivados de pirrolo[2,3-d]pirimidina
AR088246A1 (es) Derivados de etinilo
AR100940A1 (es) Derivados de 1,2,4-triazoles plaguicidas, y sus intermediarios, composiciones y sus procesos relacionados
AR101359A1 (es) Derivados de 2-oxa-5-azabiciclo[2.2.1]heptan-3-ilo
AR116713A1 (es) COMPUESTOS DE IMIDAZOLINDIONA COMO REGULADORES DE CANALES Kv3

Legal Events

Date Code Title Description
FB Suspension of granting procedure